In accordance, TGVs located in most- or standard-actionable genes accounted for most germline relevant variants (30/44), many of which have a GCR ≥50% in any tumor and age context (63%; 19/30): ATM, BRCA1, BRCA2, CHEK2, FLCN, MLH1, MSH2, and RET. Clinical judgment due to related phenotypes (AXIN2, CDH1, MEN1, MUTYH, NF1, RNF43, and VHL), was an important factor for recommending GGT testing, regardless of VAF or GCR. The gene discussed is MSH2; the disease is neoplasm.